Apolipoprotein A1 (Apo A1)
| Product Name | Apolipoprotein A1 |
| Source | Human Plasma |
| Catalogue Number | 125-12 |
| Purity | > 90% (SDS-PAGE) |
| Form | Liquid |
| Protein | > 0.5 mg/mL (BCA vs. BSA standard) |
| Appearance | Clear solution |
| Solubility | Soluble in aqueous buffers at < 50 μg/mL. Self-associates into oligomers at high concentrations in the absence of chaotropes (urea, guanidine hydrochloride). |
| Formulation | Frozen, 0.2 micron filtered solution in 50 mM tris, 150 mM sodium chloride, 0.1% sodium azide, and EDTA, pH 7.4. |
| Storage | -20°C |
| Recertification | 2 years |
| Synonyms | ApoA1, APO A1 |
| Molecular Weight | 28,300 |
Custom preparations, technical support, bulk quantities and aliquoting available, email Info@leebio.com for more details.
Apo-AI comprises ~70% of the protein moiety in HDL. It is a single polypeptide chain consisting of 245 amino acids with glutamic acid as the C-terminal residue and aspartic acid as the N-terminal residue. The molecular mass is reported to be 28.3 kDa. The protein is made up of one major isoform (pI 5.6) and two minor isoforms (pI 5.53 and 5.46). Apo-AI shows a high content of a-helix structure.
The amphipathic regions in the á-helix structure seem to be responsible for lipid binding capacity. In aqueous solution, Apo-AI shows self-association with minor conformation change. Apo-AI activates lecithin-cholesterol (LCAT) acyltransferase, which is responsible for cholesterol esterification in plasma.
Apo-AI levels in normal plasma are 90-130 mg/dL. Apo-AI levels may be inversely related to the risk of coronary disease.
Lee Biosolutions, Inc
